

Vascular Closure Device


Active closure for rapid hemostasis to accelerate patient mobility and enable same-day discharge¹⁻⁴

PRODUCT COMPARISON CHART		
	ANGIO-SEAL STS PLUS Introduced in 2002	ANGIO-SEAL VIP Designed for complete arteriotomy coverage⁵
PRODUCTS	and desired	
	Self-Tightening Suture (STS)	V-Twist Integrated Platform
MECHANISM OF ACTION	Active closure intravascular anchor and extravascular plug	
DEPLOYMENT	Manual	
COLLAGEN COMPACTION	Manual	
BIOABSORBABLE COMPONENTS	Suture, collagen and anchor resorb within 60-90 days ⁶	
ANCHOR DIMENSIONS	10.3 mm x 1.96 mm x 1 mm / 0.405" x 0.77" x 0.039"	
ANCHOR COMPOSITION	50:50 blend bioabsorbable lactide and glycolide polymers	
SUTURE TYPE	Polyglycolic acid (PGA) suture (uncoated)	Polyglycolic acid (PGA) suture with polycaprolate coating
SUTURE WEAVE	5-Hole Weave	9-Hole V-Twist
COLLAGEN PLUG DIMENSIONS	8Fr: 0.3" x 0.750" x 0.12" 6Fr: 0.3" x 0.750" x 0.08"	8Fr: 0.2" x 1.6" x 0.1" 6Fr: 0.2" x 1.6" x 0.06"
COLLAGEN PLUG COVERAGE		
PRODUCT USAGE	<10% of ANGIO-SEAL Vascular Closure Devices used worldwide ⁷	>75% of ANGIO-SEAL Vascular Closure Devices used worldwide ⁷

FIND OUT MORE Phone: 800.862.4143 terumois.com Fax: 800.411.5870







INTERVENTIONAL

SYSTEMS

Indications: The Angio-Seal Vascular Closure Device product family, including the STS Plus, VIP and Evolution platforms, is indicated for use in closing and reducing time to hemostasis of the femoral arterial puncture site in patients who have undergone diagnostic angiography procedures or interventional procedures using an 8 French or smaller procedural sheath for the 8 F Angio-Seal device and a 6 French or smaller procedural sheath for the 6 F Angio-Seal device. The Angio-Seal STS Plus, VIP and Evolution platform devices are also indicated for use to allow patients who have undergone diagnostic angiography to safely ambulate as soon as possible after sheath removal and device placement, as well as to allow patients who have undergone an interventional procedure to safely ambulate after sheath removal and device placement.

RX ONLY. Refer to the product labels and package insert for complete warnings, precautions, potential complications, and instructions for use.

1. Kapadia SR, Raymond R, Knopf W, Jenkins S, Chapekis A, Ansel G, Rothbaum D, Kussmaul W, Teirstein P, Reisman M, Casale P, Oster L, Simfendorfer C. The 6Fr Angio-Seal arterial closure device: Results from a multimember prospective registry. Am J Cardiol. 2001; 87:789-791. 2. Abando A, Hood D, Weaver F, Katz S. The use of the Angioseal device for femoral-artery closure. J Vasc Surg. 2004 Aug; 40(2):287-90. 3. Yee KM, Lazzam C, Richards J, Ross J, Seidelin PH. Same-day discharge after coronary stenting: a feasibility study using a hemostatic femoral puncture closure device. J Interv Cardiol. 2004 Oct;17(5):315-20. 4. Antonsen L., Jensen L.O, Thayssen P. Outcome and safety of same-day discharge percutaneous coronary interventions with femoral access: a single-center experience. Am-Heart J. 2013 Mar;165(3):393-9. doi: 10.1016/j.ahj.2012.11.009. 5. Huang PH, Hassan AKM, Resnic FS. Manual, mechanical, and device hemostasis. In: Lanzer P. (ed) Textbook of Catheter-Based Cardiovascular Interventions. Cham, Switzerland: Springer; 2018: 435-463. 6. Nash JE, Evans DG. The Angio-Seal hemostatic puncture closure device.

©2019 Terumo Medical Corporation. All rights reserved. All brand names are trademarks or registered trademarks of their respective owners. PM-02628

Concept and experimental results. Herz. 1999; 24(8), 597-606. 7. Data on file.